Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.
Sofia
S
Jönsson
Bob
B
Olsson
Claes
C
Ohlsson
Mattias
M
Lorentzon
Dan
D
Mellström
Hans
H
Wadenvik
D000368:Aged; D001549:Benzamides; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D015726:Giant Cells / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D013997:Time Factors
D001549:Benzamides; D010710:Phosphates; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D002118:Calcium